Eagle Pharmaceuticals Names
David Pernock President
Eagle Pharmaceuticals, Inc. named David Pernock as president
and chief commercial officer, effective January. Pernock will
be responsible for all commercial strategy and execution for
Eagle’s growing product portfolio, including the launch of
expanded indications for Ryanodex for exertional heat stroke
(EHS) and drug-induced hyperthermia, if approved by the FDA.
He will report to Scott Tarriff, Eagle’s chief executive officer.
Pernock commented: “If approved, Ryanodex for EHS would
address the needs of new patient populations for whom no
pharmaceutical treatment options are currently available. We
view the potential launch of Ryanodex as a very
significant opportunity and are committed to allocating
the resources required to help ensure a successful
Read more at: http://bit.do/c4sgw
Astellas Completes Acquisition
of Ganymed Pharmaceuticals
Astellas Pharma Inc. completed the acquisition of Ganymed
Pharmaceuticals AG, a biopharmaceutical company located in
Mainz, Germany, and Ganymed has become a wholly owned
subsidiary of Astellas as of CET December 20, 2016.
Under the agreement executed between Astellas and
Ganymed's shareholders, Astellas paid EUR 422 million to
acquire 100% of the equity in Ganymed. In addition, Ganymed's
shareholders will become eligible to receive up to
EUR 860 million in further contingent payments
based on progress in the development of IMAB362,
Ganymed's most advanced clinical program.
Read more at: http://bit.do/c4sgY
Novartis Out-Licenses Three COPD
Products in the U.S.
Astellas Pharma Inc. and Immunomic Therapeutics, Inc.
announced that the FDA granted Fast Track designation for
the drug candidate ASP0892 for the mitigation of severe
hypersensitivity reactions due to peanut allergy, a potentially life-threatening anaphylaxis induced by trace exposure.
The estimated prevalence in the U.S. for peanut allergy is
reported as 1.3% overall, 1.4% in children, and 0.6% in adults.
There is no currently approved treatment for preventing peanut-induced allergic reactions in the event of accidental ingestion.
Currently patients manage their condition by strict allergen
avoidance and carrying epinephrine auto-injectors
for use in case of accidental exposure. In the case
of children, this vigilance must also be maintained by
parents, schools, and other guardians.
Read more at: http://bit.do/c4sfC
FDA Fast Tracks Peanut Allergy